Skip to content

CONMED CNMD Finite-Lived Intangible Assets, Accumulated Amortization

Finite-Lived Intangible Assets, Accumulated Amortization at other companies

Boston Scientific logo
Boston ScientificBSX
Medtronic logo
MedtronicMDT
IAR
Integra LifeSciencesIART
Solventum logo
SolventumSOLV
Globus Medical logo
Globus MedicalGMED
Haemonetics logo
HaemoneticsHAE

Other financials

Income statement

See full
Revenue$317.0M-1.3%
Gross profit$183.4M+3.2%
Operating income$25.4M+59.3%
Net income$13.8M+129%
EPS (diluted)$0.45+137%

Balance sheet

See full
Cash & equivalents$35.0M-1.3%
Total debt$862.6M-3.6%
Total equity$1.0B+4.1%
Total assets$2.3B+0.8%

Cash flow

See full
Operating cash flow$13.5M-67.6%
CapEx$2.9M-23.5%
Free cash flow$10.6M-72.0%

Valuation

See full
Market cap$1.04B-35.6%
Enterprise value$1.87B-24.5%
P/E19×+5.4×
P/S0.8×-0.5×

Profitability

See full
Gross margin55.2%-1.0pp
Operating margin8.2%-5.6pp
Net margin4%-5.0pp
FCF margin9%-3.5pp

Returns & leverage

See full
Return on equity5.5%-7.5pp
Debt / equity0.8×-0.1×
Current ratio2.3×0.0×

Where this comes from

Reported directly by CONMED in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization.

The official record: CONMED’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about CONMED's finite-lived intangible assets, accumulated amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CONMED's finite-lived intangible assets, accumulated amortization?
CONMED (CNMD) reported finite-lived intangible assets, accumulated amortization of $437.58M in Q1 2026.
How has CONMED's finite-lived intangible assets, accumulated amortization changed year-over-year?
CONMED's finite-lived intangible assets, accumulated amortization increased by 8.7% year-over-year, from $402.4M to $437.58M.
What is the long-term trend for CONMED's finite-lived intangible assets, accumulated amortization?
Over 5 years (2020 to 2025), CONMED's finite-lived intangible assets, accumulated amortization has grown at a 10.8% compound annual growth rate (CAGR), from $257.14M to $428.87M.